BAL PHARMA LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 100.6 INR | +1.31% |
|
-0.89% | +0.50% |
| Sales 2022 | 2.81B 33.7M 2.66B | Sales 2023 | 3.04B 36.46M 2.88B | Capitalization | 1.05B 12.59M 993M |
|---|---|---|---|---|---|
| Net income 2022 | 56M 671K 52.98M | Net income 2023 | 25M 300K 23.65M | EV / Sales 2022 | 0.93 x |
| Net Debt 2022 | 1.01B 12.08M 954M | Net Debt 2023 | 1.26B 15.06M 1.19B | EV / Sales 2023 | 0.76 x |
| P/E ratio 2022 |
29.1
x | P/E ratio 2023 |
40.8
x | Employees | 869 |
| Yield 2022 |
0.93% | Yield 2023 |
1.49% | Free-Float | 33.71% |
More Fundamentals
* Assessed data
More news
More recommendations
| 1 day | +1.31% | ||
| 1 week | -0.89% | ||
| Current month | +1.51% | ||
| 1 month | +1.21% | ||
| 3 months | -11.49% | ||
| 6 months | -0.05% | ||
| Current year | +0.50% |
1 week
95.15
101.95
1 month
95.15106.00
Current year
88.95132.45
1 year
81.20132.45
3 years
63.35148.85
5 years
23.00148.85
10 years
23.00167.90
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | 31/07/94 | |
| Director of Finance/CFO | - | 01/06/23 | |
Abdul Basith
CMP | Compliance Officer | - | 16/07/23 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | 31/07/94 | |
C. V. Srinivas
BRD | Director/Board Member | 58 | 28/06/19 |
| Director/Board Member | - | 27/09/19 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 16/05/24 | 100.6 | +1.31% | 16 927 |
| 15/05/24 | 99.25 | -0.55% | 9,951 |
| 14/05/24 | 99.8 | +0.91% | 7,003 |
| 13/05/24 | 98.9 | +1.28% | 15,842 |
| 10/05/24 | 97.65 | -1.86% | 11,188 |
Delayed Quote NSE India S.E., May 16, 2024 at 12:40 pm
More quotes
Bal Pharma Limited is a fully integrated pharmaceutical company. The Company is engaged in the manufacturing and marketing of pharmaceutical formulations and active pharmaceutical ingredients (API). It is specialized in bulk actives, prescription drugs, generics and pharma intermediates. Its focused therapeutic areas are anti-diabetes, anti-histamine, anti-inflammatory, acne treatment, gastroenterology, cardiology, and dermatology. It offers a range of APIs, which includes antihistamine, platelet inhibitor, anti-diabetic, anti-convulsant, urinary incontinence, neuropathic pain, anti-allergy, anti-inflammatory, diuretic, and acne treatment. Its finished formulation products cover dosage forms, such as tablets, capsules, syrups, suspensions, IV infusions, ophthalmic, creams and ointments. The Company offers a range of natural medicine, which includes ANARSHA, ASHWAMED, AYURFINE, AYURFINE FORTE, AYURSULIN, IMMUWIN, LIPIVED, MENOLEAP CAPSULES, MENOLEAP SYRUP, PROLIFE, and BALPRO SYRUP.
Sector
Pharmaceuticals
Calendar
27/05/2024
- Q4 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +32.36% | 709B | |
| +30.77% | 595B | |
| -1.60% | 367B | |
| +20.07% | 334B | |
| +6.04% | 289B | |
| +14.77% | 239B | |
| +9.13% | 211B | |
| -3.97% | 203B | |
| +9.27% | 171B |
- Stock Market
- Equities
- BALPHARMA Stock
- BALPHARMA Stock
